Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance
Jia Liu, Max Farrow, Sandra S. Hsing, Rasha Cosman et autres
0 citationsClinical Cancer Research
Charlotte Lemech
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
214Publications signalées
2614Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
CAR-T cell therapy researchProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsCancer Immunotherapy and BiomarkersOvarian cancer diagnosis and treatment
Publications récentes
Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Data from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.